U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 2 of 2 results

TREHALOSE

MORE DETAILS

  B8WCK70T7I

Status:
Possibly Marketed Outside US
First approved in 1958
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Serine/threonine-protein kinase AKT
29
Conditions:
Oculopharyngeal muscular dystrophy
2
Spinocerebellar ataxia, type 3
2
Dry eye syndrome
21
Bipolar depression
9
Trehalose, a naturally occurring disaccharide of glucose that appears to function in an anhydrobiotic capacity in many organisms. Bioblast Pharma study trehalose in Phase 2 for treating patients with Oculopharyngeal Muscular Dystrophy (OPMD) and spin...

TREHALOSE DIHYDRATE

MORE DETAILS

  7YIN7J07X4

Status:
Possibly Marketed Outside US
First approved in 1958
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Serine/threonine-protein kinase AKT
29
Conditions:
Oculopharyngeal muscular dystrophy
2
Spinocerebellar ataxia, type 3
2
Dry eye syndrome
21
Bipolar depression
9
Trehalose, a naturally occurring disaccharide of glucose that appears to function in an anhydrobiotic capacity in many organisms. Bioblast Pharma study trehalose in Phase 2 for treating patients with Oculopharyngeal Muscular Dystrophy (OPMD) and spin...
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966